Immunotherapy for early breast cancer: too soon, too superficial, or just right?
- PMID: 33307202
- DOI: 10.1016/j.annonc.2020.11.022
Immunotherapy for early breast cancer: too soon, too superficial, or just right?
Abstract
Immunotherapy emerged as a new treatment modality for breast cancer, and its use is approved in combination with chemotherapy for first-line therapy in metastatic triple-negative breast cancer overexpressing PD-L1. As immune checkpoint inhibitors alone have modest clinical activity in advanced breast cancer, there is a growing interest in combinatorial modalities, and particularly for their rapid development in the early disease setting. The plethora of ongoing immunotherapy trials in early breast cancer comes at a time when solid data in advanced disease are still imperfect. This review offers a perspective on the efforts to establish the efficacy and safety of immunotherapeutic agents in early breast cancer.
Keywords: Immunotherapy; clinical trials; early breast cancer.
Copyright © 2020 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.
Conflict of interest statement
Disclosure ER: Investigator-initiated trial (funds paid to institution): AstraZeneca, BMS. Consultancy/advisory board: Astra Zeneca, Merck, Roche, Pierre Fabre. MP: Board member (scientific board): Oncolytics, Radius. Consultant (honoraria): AstraZeneca, Camel-IDS, Crescendo Biologics, Debiopharm, G1 Therapeutics, Genentech, Huya, Immunomedics, Lilly, Menarini, MSD, Novartis, Odonate, Oncolytics, Periphagen, Pfizer, Roche, Seattle Genetics. Research grants to her institute: AstraZeneca, Lilly, MSD, Novartis, Pfizer, Radius, Roche-Genentech, Servier, Synthon. Speaker's bureau/stock ownership: none. MAF has declared no conflicts of interest.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials